ReqMed Company,Ltd.
| Code | Sector | Market |
|---|---|---|
| 529A | Pharmaceuticals | Growth |
| Date of listing approval | 2026/02/26 |
|---|---|
| Expected Date | 2026/04/02 |
| Lead Underwriter | Nomura Securities Co., Ltd |
| Description |
| Listed Shares(total) | 1,339,300 |
|---|---|
| Trading Unit | 100 |
| New Shares | 1,339,300 |
| Existing Shares | 0 |
| Shares Outstanding | PreIPO 6,828,000.00 |
| PostIPO 8,167,300.00 | |
| Paid Up Capital | PreIPO Y100,000,000 |
| PostIPO | |
| Expected Pricing Date | 2026/03/13 |
| Book Building Start | 2026/03/17 |
| Book Building End | 2026/03/23 |
| Fix Date | 2026/03/24 |
| Offering Starts | 2026/03/25 |
| Offering Ends | 2026/03/30 |
| Expect Pricing | - |
| Notional PER (based on previous period) |
- |
| Offering Price | |
| Offering Price PER (based on previous period) |
- |
| Offering Price PBR (based on previous period) |
|
| Use of Funds Raised |
Financial Data
Units:Y1,000
| Fiscal Year End:2023/03 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 49,571 |
| Current Profit | - | -329,555 |
| Net Profit | - | -329,845 |
| Net Assets | - | 40,739 |
| Fiscal Year End:2024/03 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 318,881 |
| Current Profit | - | -211,268 |
| Net Profit | - | -227,671 |
| Net Assets | - | 1,022,805 |
| Fiscal Year End:2025/03 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 479,403 |
| Current Profit | - | -115,979 |
| Net Profit | - | -120,660 |
| Net Assets | - | 902,144 |
| Recent Quarter 2025/09 |
||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 230,536 |
| Current Profit | - | -466,738 |
| Net Profit | - | -467,213 |
| Net Assets | - | 1,763,101 |
Per Share Units:Y1
| Fiscal Year End:2023/03 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - |
| Equity | -86.09 | 10.63 |
| Fiscal Year End:2024/03 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - |
| Equity | -51.35 | 191.09 |
| Fiscal Year End:2025/03 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - |
| Equity | -22.54 | 168.55 |
| Fiscal Year End:Interim Results 2025/09 |
||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | ||
| Net Earning | - | -74.90 |
| Equity | - | - |
Comment
| ąŁOver allotment (200,800) |
Consolidated Subsidiaries
| Name | Address |
|---|
Underwriters
| Allocation | Underwriter | Tel |
|---|---|---|
| 0% | Nomura | 03-3211-1811 |
| 0% | Nomura Securities Co., Ltd | 03-3211-1811 |
| 0% | OKASAN SECURITIES GROUP INC | 03-3272-2211 |
| 0% | Marusan Securities Co., Ltd | 03-3272-5211 |
| 0% | SBI SECURITIES Co.,Ltd. | 03-5562-7210 |
| 0% | Matsui Securities Co., Ltd | 03-5216-0606 |
Data
| Date of incorporation | 1998/05/12 |
|---|---|
| Company address | Tokyo 194-0022 |
| Telephone | 042-732-2207 |
| President | |
| Homepage | https://www.reqmed.co.jp/ |
| Auditor | RSM Seiwa |
| Major Shareholders | |
|---|---|
| Shareholder Name | Ratio |
| 86.62% | |
| 11.87% | |
| 10.02% | |
| 8.38% | |
| 8.38% | |
| 5.57% | |
| 4.76% | |
| 3.89% | |
| 3.58% | |
| 3.55% | |
| 3.35% | |
| Number of Employees | 22 as of 2026/01/31 |
|---|---|
| Birth Date of Representative | 1953/06/24 |